Plus Therapeutics (PSTV) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• Over 600 companies presented across sectors like biotechnology, clean energy, fintech, metals, mining, and medical devices.

• Focus on novel radiotherapeutics for CNS tumors, with Plus Therapeutics highlighted as a top stock pick.

Technology and clinical strategy

• Lead drug rhenium obisbemeda uses rhenium-186 in nanoparticle form for targeted CNS delivery, overcoming blood-brain barrier limitations.

• Mature, scalable supply chain enables rapid drug manufacturing and delivery.

• Recent addition of CNS cancer biomarker technology and diagnostic potentially doubles the addressable market.

Clinical programs and results

• Three active clinical programs: leptomeningeal cancer, recurrent glioblastoma, and pediatric brain cancer, all with substantial external funding totaling $25 million.

• Leptomeningeal cancer trial shows high radiation delivery, minimal systemic toxicity, and promising survival signals, with median overall survival of 12 months.

• Glioblastoma program demonstrates up to 20x radiation delivery over EBRT, with median overall survival of 17 months for therapeutically dosed patients.

• Pediatric brain cancer trial funded by the DOD is expected to start this year.